Gilead Sciences, Inc. $GILD Shares Acquired by Prosperity Consulting Group LLC

Prosperity Consulting Group LLC increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 16.2% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 29,404 shares of the biopharmaceutical company’s stock after purchasing an additional 4,107 shares during the period. Prosperity Consulting Group LLC’s holdings in Gilead Sciences were worth $3,260,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in shares of Gilead Sciences by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock worth $13,162,606,000 after purchasing an additional 1,942,433 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Gilead Sciences by 314.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after purchasing an additional 11,156,382 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Gilead Sciences by 12.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock worth $1,541,302,000 after purchasing an additional 1,520,809 shares during the period. Nuveen LLC purchased a new position in shares of Gilead Sciences during the 1st quarter worth approximately $620,415,000. Finally, Nordea Investment Management AB boosted its position in shares of Gilead Sciences by 39.8% during the 2nd quarter. Nordea Investment Management AB now owns 3,956,933 shares of the biopharmaceutical company’s stock worth $436,648,000 after purchasing an additional 1,126,886 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $122.05 on Tuesday. Gilead Sciences, Inc. has a 12 month low of $86.08 and a 12 month high of $124.61. The firm has a market capitalization of $151.44 billion, a P/E ratio of 24.31, a P/E/G ratio of 0.81 and a beta of 0.34. The company’s fifty day moving average price is $115.81 and its 200 day moving average price is $111.78. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. During the same period in the previous year, the firm earned $2.02 EPS. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. Gilead Sciences’s dividend payout ratio is presently 48.99%.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Citigroup raised their price target on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Wednesday, October 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $135.00 price target on shares of Gilead Sciences in a research report on Friday. Sanford C. Bernstein reissued an “outperform” rating on shares of Gilead Sciences in a research report on Monday. UBS Group raised their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research report on Friday, August 8th. Finally, Wolfe Research raised their price target on shares of Gilead Sciences from $135.00 to $140.00 and gave the company an “outperform” rating in a research report on Thursday, October 23rd. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and an average price target of $124.65.

Insider Buying and Selling at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $354,240.00. Following the transaction, the insider owned 110,193 shares of the company’s stock, valued at approximately $13,011,589.44. This represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $295,200.00. Following the transaction, the chief financial officer owned 157,055 shares in the company, valued at $18,545,054.40. This trade represents a 1.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 71,500 shares of company stock worth $8,336,040. 0.27% of the stock is owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.